Fabry's disease historical perspective: Difference between revisions
Jump to navigation
Jump to search
Neepa Shah (talk | contribs) No edit summary |
|||
| Line 6: | Line 6: | ||
==Historical Perspective== | ==Historical Perspective== | ||
=== Discovery === | |||
* Anderson - Fabry disease was first described at the end of the 19th century by two dermatologists, Johannes Fabry in Germany and William Anderson in England. | |||
*In | * In 1989 the origin of one of its many clinical names, "angiokeratoma corporis diffusum" was first identified by fabry as he described a clinical case of a13-year-old patient affected by nodular purpura and subsequent albuminuria. In that same year Anderson described the clinical case of a systemic disorder affecting a patient aged 39 with angiokeratomas, proteinuria, finger deformities, varicose veins and lymphedema. | ||
*In | * The first ten years of the 20th century identified other similar cases. | ||
*In 1960 it was established that [[Fabry's disease]] is an [[X linked inheritance|X- linked disease]] due to deficiency of [[alpha-galactosidase]]. | * In the year 1912, Madden illustrated the clinical case of a young Egyptian patient with diffuse angiokeratomas followed in 1915 by Fabry who reproposed this condition as "Angiokeratoma corporis naeviforme". | ||
*In | * In 1947 Pompen speculated the origin of Anderson - Fabry disease as rather “familial” after the clinical case of two brothers dying of a similar disease was identified. | ||
* Anderson - Fabry Disease is a multi-systemic disorder caused by the build-up inside lysosomes of globotriaosylceramide or Gb3, the accumulated lipid material discovered in 1963 by Sweeley e Klionsky.In | |||
* In 1960 it was established that [[Fabry's disease]] is an [[X linked inheritance|X- linked disease]] due to deficiency of [[alpha-galactosidase]]. | |||
* In 1964 the clinical features of the main two phenotypes of the disease, the classical form and the atypical variants were described. | |||
* In the ‘70s the enzyme involved in the metabolism of Gb3 was found to be α-galactosidase A, whose functional deficit causes the disease. The enzyme is encoded by the GLA gene - described in 1974 - located in the long arm of the X chromosome (q21-22). | |||
* In the mid-1990s the many efforts to replace the lacking enzyme were successful and further led to the enzymatic replacement therapy for Anderson - Fabry disease.[1] | |||
*In 2003 specific treatment for [[Fabry's disease]] namely [[Fabrazyme]] was introduced. | |||
==References== | ==References== | ||
Revision as of 21:32, 16 August 2020
|
Fabry's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fabry's disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Fabry's disease historical perspective |
|
Risk calculators and risk factors for Fabry's disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Neepa Shah, M.B.B.S.[2]
Historical Perspective
Discovery
- Anderson - Fabry disease was first described at the end of the 19th century by two dermatologists, Johannes Fabry in Germany and William Anderson in England.
- In 1989 the origin of one of its many clinical names, "angiokeratoma corporis diffusum" was first identified by fabry as he described a clinical case of a13-year-old patient affected by nodular purpura and subsequent albuminuria. In that same year Anderson described the clinical case of a systemic disorder affecting a patient aged 39 with angiokeratomas, proteinuria, finger deformities, varicose veins and lymphedema.
- The first ten years of the 20th century identified other similar cases.
- In the year 1912, Madden illustrated the clinical case of a young Egyptian patient with diffuse angiokeratomas followed in 1915 by Fabry who reproposed this condition as "Angiokeratoma corporis naeviforme".
- In 1947 Pompen speculated the origin of Anderson - Fabry disease as rather “familial” after the clinical case of two brothers dying of a similar disease was identified.
- Anderson - Fabry Disease is a multi-systemic disorder caused by the build-up inside lysosomes of globotriaosylceramide or Gb3, the accumulated lipid material discovered in 1963 by Sweeley e Klionsky.In
- In 1960 it was established that Fabry's disease is an X- linked disease due to deficiency of alpha-galactosidase.
- In 1964 the clinical features of the main two phenotypes of the disease, the classical form and the atypical variants were described.
- In the ‘70s the enzyme involved in the metabolism of Gb3 was found to be α-galactosidase A, whose functional deficit causes the disease. The enzyme is encoded by the GLA gene - described in 1974 - located in the long arm of the X chromosome (q21-22).
- In the mid-1990s the many efforts to replace the lacking enzyme were successful and further led to the enzymatic replacement therapy for Anderson - Fabry disease.[1]
- In 2003 specific treatment for Fabry's disease namely Fabrazyme was introduced.